Abstracts tagged "autoimmune diseases"

Abstract Number: 678 • 2012 ACR/ARHP Annual Meeting
Estrogen Modulation of ZAS3 Is Mediated Through Estrogen Receptor α: An Underlying Mechanism of Gender-Bias in Systemic Lupus Erythematosus?
Nicholas Young¹, Alexandra Friedman², Lai-Chu Wu² and Wael N. Jarjour³, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Global population data has indicated that post-pubertal females have decreased rates of infectious diseases when compared to male counterparts and preadolescent or postmenopausal females. …
Abstract Number: 2503 • 2012 ACR/ARHP Annual Meeting
CD8+Foxp3-CD103+ Regulatory T Cells Generated Ex Vivo with TGF-β Suppress Autoimmunity Through IL-10-Dependet Mechanism
Ya Liu¹, An-Ping Xu², David A. Horwitz³ and Song G. Zheng⁴, ¹Medicine, USC Keck School of Medicine, Los Angeles, CA, ²Kidney disease and rheumatology, 2nd Affiliated Hospital of Sun Yat-sen University, ³Medicine-Rheumatology-Immun, Keck School of Medicine of USC, Los Angeles, CA, ⁴Medicine, Keck School of Medicine of USC, Los Angeles, CA
Background/Purpose: TGF-β is crucial for induction of CD4+Foxp3+ Tregs and maintenance of immunologic tolerance. It is, however, unclear if TGF-β also induces the similar CD8+…
Abstract Number: 660 • 2012 ACR/ARHP Annual Meeting
Abnormal Neutrophil Development in Human Systemic Lupus Erythematosus
Namrata Singh¹, Mariana J. Kaplan², Philip L. Cohen³ and Michael F. Denny³, ¹Internal Medicine, Temple University, Philadelphia, PA, ²Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ³Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: Recent research has increased the appreciation of the contributions of neutrophils to systemic lupus erythematosus (SLE). An abnormal circulating pool of granulocytes has been…
Abstract Number: 2327 • 2012 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Negative Costimulatory Fusion Protein Is Effective in the Collagen-Induced Arthritis Mouse Model of Rheumatoid Arthritis
Iris Hecht¹, Kay McNamee², Ilan Vaknin³, Anat Oren³, Joseph R. Podojil⁴, Galit Rotman³, Eyal Neria³, Stephen D. Miller⁴ and Richard O. Williams², ¹R&D, Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Compugen Ltd., Tel Aviv, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose: CGEN-15001 is a recombinant Fc fusion protein consisting of the extracellular domain of CGEN-15001T, a protein predicted to be a member of the B7/CD28…
Abstract Number: 518 • 2012 ACR/ARHP Annual Meeting
Spontaneous Sialadenitis Like Sjögren’s Syndrome in Orphan Nuclear Receptor γt (RORγt) Transgenic Mice
Mana Iizuka¹, Hiroto Tsuboi¹, Hiromitsu Asashima¹, Yuya Kondo¹, Satoru Takahashi², Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: The nuclear receptors retinoic-acid-receptor-related orphan receptors gt (RORγt) is required for the generation of Th17 cells expressing the proinflammatory cytokine IL-17. Th17 cells expressing…
Abstract Number: 2268 • 2012 ACR/ARHP Annual Meeting
Hyperacetylation of Histone H4 in Systemic Lupus Erythematosus
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Zhe Zhang³, Michelle Petri⁴ and Kathleen E. Sullivan², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Bioinformatics, Bioinformatics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease and is characterized by multi-systemic chronic inflammation. Epigenetic processes, such as posttranslational histone modifications, can…
Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Ilias Lazarou¹, Axel Finckh², Lara Fischer³, Camillo Ribi³, Joerg Seebach³ and Pierre A. Guerne², ¹University Hospitals of Geneva, Geneva, Switzerland, ²Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ³Immunology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
Abstract Number: 2271 • 2012 ACR/ARHP Annual Meeting
Variation of Interferon-Alpha Production in Healthy Individuals and Association with Autoimmune Susceptibility Genes
Olof Berggren¹, Andrei Alexsson², Gunnar V. Alm³, Ann-Christine Syvänen⁴, Lars Rönnblom² and Maija-Leena Eloranta², ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden
Background/Purpose: Many autoimmune diseases, e.g. systemic lupus erythematosus (SLE), have an activated type I interferon (IFN) system and about 40 SLE susceptibility loci, many within…
Abstract Number: 440 • 2012 ACR/ARHP Annual Meeting
Effects of Fetal Microchimerisms On Disease Onset and Severity in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Marianne Kekow¹, Sara Fill Malfertheiner², Maria Barleben¹, Susanne Drynda³, Joern Kekow³ and Thomas Brune¹, ¹Univ of Magdeburg, Children's Hospital, Magdeburg, Germany, ²Univ of Magdeburg, Department of Obstetrics and Gynecology, Magdeburg, Germany, ³Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: The major source of naturally acquired microchimerisms (MC) is the transplacental traffic of fetal cells between a mother and the fetus during pregnancy. Fetal…
Abstract Number: 1929 • 2012 ACR/ARHP Annual Meeting
Pernicious Anemia and Vitamin B-12 Deficiency in Autoimmune Disease: Neglecting the Feet Will Lead You Astray
Michael R. Lovy, Desert Oasis Healthcare, Palm Springs, CA
Background/Purpose: The occurrence of multiple autoimmune disorders in individual patients is commonly observed. Rarely, this is explained by recently recognized genetically based autoimmune polyendocrine syndromes.…
Abstract Number: 338 • 2012 ACR/ARHP Annual Meeting
The Potent Phosphoinositide-3-Kinase-(δ,γ) Inhibitor IPI-145 Is Active in Preclinical Models of Arthritis and Well Tolerated in Healthy Adult Subjects
James R. Porter¹, Janid Ali², Jonathan P. DiNitto², Joi Dunbar², Kerrie Faia², Jennifer Hoyt², Brianne Leary², Alice R. Lim², Christian Martin², Charlotte McKee², Patrick O'Hearn², Melissa Pink², Jennifer Proctor², John Soglia², Bonnie Tillotson², Kerry White², David G. Winkler² and Vito J. Palombella², ¹Product Development, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Infinity Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Phosphoinositide-3-kinases (PI3K) play pivotal roles in cell signaling and regulate a variety of cellular functions. PI3K-δ and PI3K-γ isoforms are necessary for adaptive and…
Abstract Number: 1820 • 2012 ACR/ARHP Annual Meeting
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil^®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System
Lamiae Grimaldi-Bensouda¹, Michel Rossignol², Elodie Aubrun¹, Pamela Leighton³, Didier Guillemot⁴, Alfred Mahr⁵, Jacques Benichou⁶, Paul-Henri Lambert⁷, Bertrand Godeau⁸ and Lucien Abenhaim⁹, ¹LA-SER, Paris, France, ²LA-SER, Centre for Risk Research, Montreal, Canada, ³LA-SER Europe Ltd., London, United Kingdom, ⁴Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris-Ile de France Ouest, Paris, France, ⁵Internal Medicine, Hospital Saint-Louis, Paris, France, ⁶INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, ⁷Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, ⁸Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁹LA-SER Europe Ltd, London, United Kingdom
Background/Purpose: This study investigated whether the human papillomavirus (HPV) vaccine [types 6, 11, 16, 18] is associated with a modified risk of autoimmune disorders (AIDs).…
Abstract Number: 341 • 2012 ACR/ARHP Annual Meeting
Oral Administration of a Novel Small Molecule BET Bromodomain Inhibitor, RVX-297, Reduces Disease Severity in a Rat Collagen-Induced Arthritis Model
R. Jahagirdar¹, S. Attwell¹, E.M. Gesner¹, K.G. McLure¹, H.C. Hansen¹, J. Chen², J. Wu¹, K. Norek¹, N. Shenoy², G.S. Wagner¹ and P. R. Young¹, ¹Resverlogix Corporation, Calgary, AB, Canada, ²Aravasc Inc., Sunnyvale, CA
Background/Purpose: BET (Bromodomain and Extra-Terminal) proteins have recently emerged as a key epigenetic regulator of genes at the transcriptional level and inhibition of their binding…
Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting
Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Kyle P. Chiang¹, Varun Gauba¹, Darin Lee¹, Minh-Ha T. Do¹, Jie J. Zhou², Feng Wang², Ying Buechler¹, Leslie Nangle¹, Zhiwen Xu², John Mendlein¹, Melissa Ashlock¹ and Jeffrey M. Greve¹, ¹aTyr Pharma, San Diego, CA, ²Scripps Laboratory, Institute for Advanced Study, Hong Kong University of Science and Technology, Kowloon, Hong Kong
Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…
Abstract Number: 196 • 2012 ACR/ARHP Annual Meeting
Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
Alireza Meysami¹, Kevin F. Spratt² and Christopher M. Burns³, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Department of Orthopaedic Surgery, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth Medical School, Lebanon, NH
· Background/Purpose: Sarcoidosis is characterized by a variable clinical presentation. DMARDs and biologics have been used for resistant and/or organ-threatening disease. We analyzed the cases…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].